September 2017

New Product - Kanuma

Kanuma (sebelipase alfa rce) is a recombinant human lysosomal acid lipase (rhLAL). Lysosomal acid lipase deficiency (LAL-D) is a rare disease associated with significant morbidity and mortality affecting individuals from infancy through to adulthood. Treatment with sebelipase alfa rce restores LAL enzyme activity in LAL-D cells, enabling hydrolysis of cholesteryl esters and triglycerides in the lysosome. Kanuma (sebelipase alfa rce) is indicated for long-term enzyme replacement therapy in patients of all ages with LAL-D. Kanuma is contraindicated in patients with a life-threatening hypersensitivity (anaphylactic reaction) to egg. Kanuma solution for infusion 20 mg in 10 mL is supplied as a single use vial, pack of 1.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au